Peptide nucleic acid probe for multiplex detection of BCR/ABL negative myeloproliferative neoplasm-associated gene mutations
US11028428B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 3, 2016 |
| Grant date | Jun 8, 2021 |
| Priority date | — |
| Expiry date | Dec 13, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/156
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention provides a peptide nucleic acid probe including any one or more selected from the group consisting of nucleic acid sequences represented by SEQ ID NOs: 7-10 and nucleic acid sequences complementary to the nucleic acid sequences, and manufactured so as to complementarily bind to a BCR/ABL negative myeloproliferative neoplasm-associated gene, thereby enabling multiplex detection of gene mutations; a composition for multiplex detection of gene mutations comprising the same; a kit; and a method for multiplex detection of BCR/ABL negative myeloproliferative neoplasm-associated gene mutations using the same. Therefore, since multiplex detection of BCR/ABL negative myeloproliferative neoplasm-associated gene mutations can be rapidly and accurately carried out by one detection process, BCR/ABL negative myeloproliferative neoplasm is effectively diagnosed, and thus the present invention can be useful for diagnosis, follow-up, prognosis estimation, and treatment of diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.